iCo Therapeutics Inc. Provides an Update Regarding Oral Amphotericin Study, Marketing and Partnering Activities

iCo Therapeutics Inc. Provides an Update Regarding Oral Amphotericin Study, Marketing and Partnering Activities

Vancouver, British Columbia–(Newsfile Corp. – October 28, 2019) – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or “the Company”) and its Australian subsidiary, iCo Therapeutics Pty Ltd., today announced several developments related to its wholly-owned oral Amphotericin B (Oral Amp B) asset and current marketing and partnering efforts.

iCo will be holding meetings with prospective partners and investors during the following meetings:

AusBiotech 2019 (Melbourne Australia, October 30 – November 1, 2019), the premier Australian life sciences annual meeting.

ISOPT Clinical – The Retina Chapter (Valencia Spain, November 7 – November 9, 2019), The International Symposium on Ocular Pharmacology and Therapeutics.

BIO Europe (Hamburg Germany, November 10-November 13, 2019), Europe’s key Fall 2019 life sciences partnering meeting.

iCo has also engaged Bello Capital Partners to assist the Company with a social media and marketing campaign. Bello has been paid $50,000 CDN to assist with these services.

Certain statements included in this press release may be considered “forward-looking information” within the meaning of applicable securities laws. Forward-looking information can be identified by words such as: “anticipate”, “intend”, “plan”, “goal”, “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Forward-looking statements in this press release include statements relating to the timing and completion of the Private Placement and the use of proceeds therefrom. All forward-looking statements are based on iCo’s current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


Andrew Rae
Chief Executive Officer
iCo Therapeutics Inc.
1-778-772-7775 (c)